Saltz L - Search Results

1

False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.

Litvak A, Cercek A, Segal N, Reidy-Lagunes D, Stadler ZK, Yaeger RD, Kemeny NE, Weiser MR, Pessin MS, Saltz L. Litvak A, et al. Among authors: saltz l. J Natl Compr Canc Netw. 2014 Jun;12(6):907-13. doi: 10.6004/jnccn.2014.0085. J Natl Compr Canc Netw. 2014. PMID: 24925201 Free PMC article.

2

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: saltz lb. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

3

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Conti JA, et al. Among authors: saltz lb. J Clin Oncol. 1996 Mar;14(3):709-15. doi: 10.1200/JCO.1996.14.3.709. J Clin Oncol. 1996. PMID: 8622015

4

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.

5

Adjuvant treatment of colorectal cancer.

Saltz LB, Kelsen DP. Saltz LB, et al. Annu Rev Med. 1997;48:191-202. doi: 10.1146/annurev.med.48.1.191. Annu Rev Med. 1997. PMID: 9046955 Review.

6

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. Saltz LB, et al. Cancer. 1997 Nov 1;80(9):1727-32. doi: 10.1002/(sici)1097-0142(19971101)80:9<1727::aid-cncr5>3.0.co;2-b. Cancer. 1997. PMID: 9351540 Clinical Trial.

7

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D. Saltz LB, et al. J Clin Oncol. 1998 Dec;16(12):3858-65. doi: 10.1200/JCO.1998.16.12.3858. J Clin Oncol. 1998. PMID: 9850031 Clinical Trial.

8

A phase II study of irinotecan in patients with advanced hepatocellular carcinoma.

O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB. O'Reilly EM, et al. Among authors: saltz lb. Cancer. 2001 Jan 1;91(1):101-5. doi: 10.1002/1097-0142(20010101)91:1<101::aid-cncr13>3.0.co;2-k. Cancer. 2001. PMID: 11148565 Clinical Trial.

9

A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma.

Sanz-Altamira PM, O'Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, Saltz LB. Sanz-Altamira PM, et al. Among authors: saltz lb. Ann Oncol. 2001 Apr;12(4):501-4. doi: 10.1023/a:1011135014895. Ann Oncol. 2001. PMID: 11398883 Free article. Clinical Trial.

10

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

Sharma S, Kemeny N, Schwartz GK, Kelsen D, O'Reilly E, Ilson D, Coyle J, De Jager RL, Ducharme MP, Kleban S, Hollywood E, Saltz LB. Sharma S, et al. Among authors: saltz lb. Clin Cancer Res. 2001 Dec;7(12):3963-70. Clin Cancer Res. 2001. PMID: 11751488 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

508 results

Search Page

Filters